Fig. 1: Expression of FN-EDA is associated with CD31 in hepatic fibrosis.
From: FN-EDA mediates angiogenesis of hepatic fibrosis via integrin-VEGFR2 in a CD63 synergetic manner
A, B qRT-PCR analysis of FN-EDA and FN-EDB mRNA levels between liver tissue of CHD patients (n = 30) and healthy control (n = 15). (GAPDH was used as an internal control. Data are shown as the mean ± SEM. FN-EDA: ****P < 0.0001; FN-EDB: P: ns) C Masson staining in human fibrosis hepatic tissues (n = 5) and normal tissues (n = 5). (quantification relative area of Masson staining. Data are shown as mean ± SEM. *P = 0.0217. Scale bar = 200 μm. D Immunohistochemical staining of FN-EDA in human fibrosis hepatic tissues (n = 5) and normal tissues (n = 5). (Data are shown as mean ± SEM. ***P = 0.0001. Scale bar = 200 μm). E Immunohistochemical staining of CD31 in human fibrosis hepatic tissues (n = 5) and normal tissues (n = 5). (Data are shown as mean ± SEM. **P = 0.0060. Scale bar = 200 μm). F qRT-PCR analysis of correlation between FN-EDA and CD31 in human fibrosis hepatic tissues (n = 30). (R = 0.6612 ****P < 0.0001) G, H FN-EDA and CD31 staining in livers of CCl4-treated mice biweekly until tenth weeks (n = 18) (Scale bar = 200 μm; arrows: staining) I Analysis of FN-EDA and CD31 expression in IHC (n = 3).
